Drospirenone
Endothelial Dysfunction
Iuliu Hatieganu University of Medicine and PharmacySmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Endothelial Dysfunction cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
SODIUM ZIRCONIUM CYCLOSILICATE University of Erlangen-Nürnberg Medical School | Phase 3 | CCC |
ACETYLCHOLINE Stefan Soderberg | Early Phase 1 | CC |
Inomax Stefan Soderberg | Early Phase 1 | CC |
VERAPAMIL SLOW RELEASE Stefan Soderberg | Early Phase 1 | CC |
ARG-PRO-PRO-GLY-PHE-SER-PRO-PHE-ARG Stefan Soderberg | Early Phase 1 | CC |
Same molecule, other indications
Drospirenone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →